Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 10/21 10:14:59 pm
74.29 USD   -0.03%
10/20 GILEAD SCIENCES : Jolley Asset Management buys $3,491,855 stake in G..
10/20 GILEAD SCIENCES : Announces SVR12 Rates From Four Phase 3 Studies of..
10/20 GILEAD SCIENCES : Announces Top-Line Phase 2 Results for GS-4997 (Se..
News SummaryMost relevantAll newsSector news 

Gilead 1Q Net Slips 32% On Higher Expenses, Weaker Margins

share with twitter share with LinkedIn share with facebook
share via e-mail
04/26/2012 | 10:54pm CEST

Gilead Sciences Inc. (>> Gilead Sciences, Inc.) first-quarter earnings slid 32% as the biopharmaceutical company reported higher expenses and weaker margins, though adjusted profits improved.

Product sales, which generate the majority of the company's revenue, have been rising steadily in recent quarters. In the latest period, product sales rose 19%. Sales of antiviral products, its dominant revenue stream, increased 18 as HIV drugs Atripla and Truvada saw sales gains of 19% and 13%, respectively.

The company also receives royalties for Tamiflu from Roche Holding AG (RHHBY, ROG.VX). Royalty, contract and other revenue from collaborations were also up 19% last quarter.

Lately, Gilead has been focusing on simplifying HIV therapy, a treatment market that it dominates. In December, U.S. regulators accepted Gilead's new drug application for its Quad combination HIV drug, which analysts view as a potential growth driver. The Food and Drug Administration in February also granted Truvada a priority-review schedule, advancing what could become the first treatment labeled for HIV prevention.

Earlier this year, Gilead bought Pharmasset Inc. for more than $11 billion in a deal expected to accelerate the development of treatments for hepatitis C, a hotly contested market. A key drug candidate it obtained with Pharmasset, GS-7977, suffered a setback in February as a majority of hepatitis-C patients in one arm of a clinical trial had a relapse, raising questions about the drug's potential.

In the latest quarter, Gilead posted a profit of $442 million, or 57 cents a share, down from $651.1 million, or 80 cents a share, a year earlier. Excluding acquisition-related expenses, restructuring and stock-based compensation, earnings rose to 91 cents from 87 cents.

Revenue gained 19% to $2.28 billion.

Analysts polled by Thomson Reuters had expected a profit of 93 cents a share and revenue of $2.2 billion.

Operating margin narrowed to 35.1% from 46.8% as total costs and expenses jumped 45%.

Shares were down 1.4% to $52 after-hours. Through the close, the stock is up 29% since the start of the year.

   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com 

Stocks mentioned in the article : Gilead Sciences, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES, INC.
10/20 GILEAD SCIENCES : Patent Issued for Methods of Treating Patients Co-Infected wit..
10/20 GILEAD SCIENCES : Jolley Asset Management buys $3,491,855 stake in Gilead Scienc..
10/20 GILEAD SCIENCES : Announces SVR12 Rates From Four Phase 3 Studies of a Once-Dail..
10/20 GILEAD SCIENCES : Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) i..
10/14 GILEAD SCIENCES : Creative Planning buys $25,314,133 stake in Gilead Sciences
10/10 GILEAD SCIENCES : Private Asset Management Inc buys $8,511,601 stake in Gilead S..
10/07 GILEAD SCIENCES : Kempner Capital Management adds Gilead Sciences to its portfol..
10/04DJFDA Warns on Hepatitis C Drugs
10/03 NASDAQ 100 MOVERS : Ntap, ctsh
09/29 GILEAD SCIENCES : Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerat..
More news
Sector news : Bio Therapeutic Drugs
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
10/17DJPfizer Plans to Launch Remicade Biosimilar in November
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
10/21 BEST NEAR-TERM PRICE GAINS AHEAD FOR : Established Biotechnology Stocks
10/21 Why You (And Another Company) Should Buy Gilead - Dividend Sensei
10/21 Gilead Sciences Offers Some Compelling Clinical Data
10/20 Is This Berkshire-Like Move The Right Thing For Gilead?
10/20 Collaborative Leukemia Trial Orbits Moonshot Initiative
Financials ($)
Sales 2016 30 392 M
EBIT 2016 20 100 M
Net income 2016 14 611 M
Debt 2016 2 884 M
Yield 2016 2,49%
P/E ratio 2016 6,96
P/E ratio 2017 6,66
EV / Sales 2016 3,32x
EV / Sales 2017 3,28x
Capitalization 98 037 M
More Financials
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 103 $
Spread / Average Target 38%
Consensus details
EPS Revisions
More Estimates Revisions
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-26.58%98 037
AMGEN, INC.-2.35%118 623
ACTELION LTD17.34%16 178
More Results